Katsuhiko Tomooka Selected Research

2,5-dimethylcelecoxib

1/2022	2,5-Dimethylcelecoxib attenuates cardiac fibrosis caused by cryoinjury-induced myocardial infarction by suppressing the fibroblast-to-myofibroblast transformation via inhibition of the TGF-β signaling pathway.
1/2021	Cardiac and renal protective effects of 2,5-dimethylcelecoxib in angiotensin II and high-salt-induced hypertension model mice.
10/2019	2,5-Dimethylcelecoxib prevents isoprenaline-induced cardiomyocyte hypertrophy and cardiac fibroblast activation by inhibiting Akt-mediated GSK-3 phosphorylation.
2/2017	2,5-Dimethylcelecoxib prevents pressure-induced left ventricular remodeling through GSK-3 activation.
1/2017	Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathway.
7/2011	Celecoxib and 2,5-dimethyl-celecoxib prevent cardiac remodeling inhibiting Akt-mediated signal transduction in an inherited dilated cardiomyopathy mouse model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katsuhiko Tomooka Research Topics

Disease

4	Heart Failure 01/2021 - 07/2011
4	Neoplasms (Cancer) 01/2017 - 06/2014
3	Fibrosis (Cirrhosis) 01/2022 - 02/2017
3	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 10/2019 - 07/2011
2	Breast Neoplasms (Breast Cancer) 01/2021 - 12/2019
2	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 10/2019 - 02/2017
2	Cardiomegaly (Heart Hypertrophy) 02/2017 - 07/2011
1	Myocardial Infarction 01/2022
1	Chronic Renal Insufficiency 01/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Kidney Diseases (Kidney Disease) 01/2021
1	Hypertrophy 10/2019
1	Heart Diseases (Heart Disease) 02/2017
1	Ventricular Remodeling 02/2017
1	Colonic Neoplasms (Colon Cancer) 01/2017
1	Melanoma (Melanoma, Malignant) 01/2017
1	Intestinal Neoplasms (Intestinal Cancer) 01/2017
1	Carcinoma (Carcinomatosis) 01/2017
1	Body Weight (Weight, Body) 07/2011

Drug/Important Bio-Agent (IBA)

6	2,5-dimethylcelecoxibIBA 01/2022 - 07/2011
6	CateninsIBA 01/2021 - 07/2011
5	Celecoxib (Celebrex)FDA Link 01/2021 - 07/2011
4	Glycogen Synthase Kinase 3IBA 01/2022 - 01/2017
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 10/2019 - 02/2017
2	Glycogen Synthase (Synthase I)IBA 10/2019 - 02/2017
2	Cyclin D1IBA 01/2017 - 06/2014
1	Connective Tissue Growth FactorIBA 01/2022
1	CollagenIBA 01/2022
1	Ribosomal Protein S6 Kinases (S6 Kinase)IBA 01/2021
1	SaltsIBA 01/2021
1	Angiotensin IIIBA 01/2021
1	70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)IBA 01/2021
1	CyclinsIBA 12/2019
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 12/2019
1	Isoproterenol (Isoprenaline)FDA LinkGeneric 10/2019
1	TOR Serine-Threonine KinasesIBA 10/2019
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2017
1	Transcription Factors (Transcription Factor)IBA 06/2014
1	Brain Natriuretic Peptide (Natrecor)FDA Link 07/2011
1	Myosin Heavy Chains (Myosin Heavy Chain)IBA 07/2011

Therapy/Procedure

3	Oral Administration 01/2017 - 06/2014